Leigh MacMillan

May 24, 2022

Diabetes, cardiovascular drug targets

Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

By Leigh MacMillan
May 19, 2022

Genetics and blood pressure

Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

By Leigh MacMillan
Andy Weiss, PhD, Caitlin Murdoch, PhD, and colleagues have characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins.
May 17, 2022

Study identifies first cellular “chaperone” for zinc, sheds light on worldwide public health problem of zinc deficiency

A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins.

By Leigh MacMillan
May 9, 2022

Gene variants and transplant drug dose

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

By Leigh MacMillan
Erin Green, PhD, Eric Skaar, PhD, MPH, and colleagues are studying how a certain bacterial pathogen can survive on hospital surfaces for months with no water.
May 5, 2022

VUMC team discovers how bacterial pathogen survives without water

Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections.

By Leigh MacMillan
May 5, 2022

COVID-associated bleeding risk

While case reports have noted acquired hemophilia after COVID-19 infection or vaccination, a new study finds no increased risk.

By Leigh MacMillan
April 28, 2022

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.
By Leigh MacMillan
April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.
By Leigh MacMillan
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
By Leigh MacMillan
April 13, 2022

Addiction researcher Nestler set for next Discovery Lecture

Eric Nestler, MD, PhD, renowned for his studies of the molecular basis of drug addiction and depression, will deliver the next Discovery Lecture on Thursday, April 21.
By Leigh MacMillan
April 12, 2022

Financial impact of prior authorization

Prior authorization — health insurer approval of a medical intervention prior to treatment — costs more than $40 million for U.S. academic radiation oncology practices, with questionable value added to patient care.
By Leigh MacMillan
April 11, 2022

Peptides promote AFib arrhythmia

Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation.
By Leigh MacMillan
1 … 8 9 10 11 12 … 75